Allogene Therapeutics, Inc. - Common Stock, $0.001 par value per share (ALLO)
CUSIP: 019770106
Q4 2024 13F Holders as of 31 Dec 2024
- Type / Class
- Equity / Common Stock, $0.001 par value per share
- Shares outstanding
- 344,793,745
- Total 13F shares
- 188,657,885
- Share change
- -4,291,440
- Total reported value
- $401,850,158
- Put/Call ratio
- 70%
- Price per share
- $2.13
- Number of holders
- 170
- Value change
- -$12,907,825
- Number of buys
- 78
- Number of sells
- 57
Quarterly Holders Quick Answers
What is CUSIP 019770106?
CUSIP 019770106 identifies ALLO - Allogene Therapeutics, Inc. - Common Stock, $0.001 par value per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 019770106:
Top shareholders of ALLO - Allogene Therapeutics, Inc. - Common Stock, $0.001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| FMR LLC |
13F
|
Company |
8.7%
|
30,026,956
|
$84,075,477 | — | 30 Sep 2024 | |
| TPG GP A, LLC |
3/4/5
13F
|
10%+ Owner · Company |
5.4%
from 13F
|
18,716,306
|
$59,413,042 | — | 12 Jan 2022 | |
| BlackRock, Inc. |
13F
|
Company |
5.2%
|
17,772,745
|
$49,763,686 | — | 30 Sep 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
2.4%
|
8,327,699
|
$23,317,557 | — | 30 Sep 2024 | |
| STATE STREET CORP |
13F
|
Company |
2%
|
7,013,083
|
$19,636,632 | — | 30 Sep 2024 | |
| Capital World Investors |
13F
|
Company |
2%
|
6,896,552
|
$19,310,346 | — | 30 Sep 2024 | |
| Lynx1 Capital Management LP |
13F
13D/G
|
Company |
5.2%
from 13D/G
|
6,202,374
|
$17,366,647 | — | 30 Sep 2024 | |
| PRIMECAP MANAGEMENT CO/CA/ |
13F
|
Company |
1.6%
|
5,668,260
|
$15,871,128 | — | 30 Sep 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
1.5%
|
5,039,594
|
$14,110,863 | — | 30 Sep 2024 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
1.4%
|
4,838,743
|
$13,550,000 | — | 30 Sep 2024 | |
| Woodline Partners LP |
13F
|
Company |
1.3%
|
4,364,300
|
$12,220,040 | — | 30 Sep 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
1.2%
|
4,087,506
|
$11,445,016 | — | 30 Sep 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.94%
|
3,227,104
|
$9,037,474 | — | 30 Sep 2024 | |
| Wildcat Capital Management, LLC |
13F
|
Company |
0.85%
|
2,920,787
|
$8,178,204 | — | 30 Sep 2024 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
0.83%
|
2,867,750
|
$8,029,700 | — | 30 Sep 2024 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.81%
|
2,797,970
|
$7,834,316 | — | 30 Sep 2024 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.79%
|
2,730,480
|
$7,646,573 | — | 30 Sep 2024 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
0.79%
|
2,725,000
|
$7,630,000 | — | 30 Sep 2024 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.7%
|
2,410,400
|
$6,749,120 | — | 30 Sep 2024 | |
| Eric Thomas Schmidt |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
2,447,772
mixed-class rows
|
$6,396,524 | — | 22 Mar 2023 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.63%
|
2,162,603
|
$6,055,288 | — | 30 Sep 2024 | |
| Vida Ventures Advisors, LLC |
13F
|
Company |
0.52%
|
1,798,163
|
$5,034,856 | — | 30 Sep 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.5%
|
1,721,530
|
$4,820,285 | — | 30 Sep 2024 | |
| ExodusPoint Capital Management, LP |
13F
|
Company |
0.47%
|
1,634,838
|
$4,578,000 | — | 30 Sep 2024 | |
| Vestal Point Capital, LP |
13F
|
Company |
0.44%
|
1,500,000
|
$4,200,000 | — | 30 Sep 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.36%
|
1,248,539
|
$3,495,908 | — | 30 Sep 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.34%
|
1,178,848
|
$3,300,774 | — | 30 Sep 2024 | |
| DAFNA Capital Management LLC |
13F
|
Company |
0.3%
|
1,050,118
|
$2,940,330 | — | 30 Sep 2024 | |
| Alison Moore |
3/4/5
|
Chief Technical Officer |
—
mixed-class rows
|
1,105,469
mixed-class rows
|
$2,135,517 | — | 22 Mar 2023 | |
| TD ASSET MANAGEMENT INC |
13F
|
Company |
0.2%
|
677,140
|
$1,970,477 | — | 30 Sep 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.19%
|
642,009
|
$1,797,625 | — | 30 Sep 2024 | |
| Veer Bhavnagri |
3/4/5
|
General Counsel |
—
class O/S missing
|
556,049
|
$1,765,122 | — | 14 Mar 2023 | |
| Rafael Amado |
3/4/5
|
EVP of R&D |
—
class O/S missing
|
541,946
|
$1,720,353 | — | 07 Oct 2022 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.17%
|
583,925
|
$1,634,990 | — | 30 Sep 2024 | |
| ZACKS INVESTMENT MANAGEMENT |
13F
|
Company |
0.15%
|
516,601
|
$1,446,482 | — | 30 Sep 2024 | |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE |
13F
|
Company |
0.14%
|
486,023
|
$1,360,864 | — | 30 Sep 2024 | |
| SUPERSTRING CAPITAL MANAGEMENT LP |
13F
|
Company |
0.14%
|
478,115
|
$1,338,722 | — | 30 Sep 2024 | |
| CITIGROUP INC |
13F
|
Company |
0.14%
|
469,310
|
$1,314,068 | — | 30 Sep 2024 | |
| NORDEA INVESTMENT MANAGEMENT AB |
13F
|
Company |
0.13%
|
451,006
|
$1,303,408 | — | 30 Sep 2024 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.13%
|
437,721
|
$1,225,619 | — | 30 Sep 2024 | |
| Cerity Partners LLC |
13F
|
Company |
0.13%
|
432,382
|
$1,210,670 | — | 30 Sep 2024 | |
| Coastal Bridge Advisors, LLC |
13F
|
Company |
0.12%
|
405,847
|
$1,136,372 | — | 30 Sep 2024 | |
| UBS Group AG |
13F
|
Company |
0.1%
|
347,340
|
$972,552 | — | 30 Sep 2024 | |
| BARCLAYS PLC |
13F
|
Company |
0.1%
|
342,973
|
$960,324 | — | 30 Sep 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.09%
|
317,619
|
$889,334 | — | 30 Sep 2024 | |
| Rafferty Asset Management, LLC |
13F
|
Company |
0.09%
|
316,946
|
$887,449 | — | 30 Sep 2024 | |
| Swiss National Bank |
13F
|
Company |
0.08%
|
264,900
|
$741,720 | — | 30 Sep 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.07%
|
258,002
|
$722,406 | — | 30 Sep 2024 | |
| PARTNERS CAPITAL INVESTMENT GROUP, LLP |
13F
|
Company |
0.07%
|
254,845
|
$713,566 | — | 30 Sep 2024 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
0.07%
|
254,239
|
$711,869 | — | 30 Sep 2024 |
Institutional Holders of Allogene Therapeutics, Inc. - Common Stock, $0.001 par value per share (ALLO) as of Q4 2024
As of 31 Dec 2024,
Allogene Therapeutics, Inc. - Common Stock, $0.001 par value per share (ALLO) was held by
170 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
188,657,885 shares.
The largest 10 holders included
FMR LLC, Pfizer Inc, TPG GP A, LLC, BlackRock, Inc., Lynx1 Capital Management LP, VANGUARD GROUP INC, STATE STREET CORP, Capital World Investors, CITADEL ADVISORS LLC, and PRIMECAP MANAGEMENT CO/CA/.
This page lists
171
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2024 vs Q3 2024 Across Filers
Q3 2024 holders
152
Q4 2024 holders
170
Holder diff
18
| Investor | Q3 2024 Shares | Q4 2024 Shares | Share Diff | Share Chg % | Q3 2024 Value $ | Q4 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.